July 31, 2020

Actuate Therapeutics announces initiation of phase 2 clinical study in pancreatic cancer
(press release)

May 29, 2020

Actuate Therapeutics announces 9-ING-41 data presentation at ASCO Annual Meeting 2020
(press release)
(ATI 1801 Study)

April 9, 2020

Actuate Therapeutics announces initiation of additional clinical studies for 9-ING-41.
(press release)

November 12, 2019

Actuate Therapeutics completes $6.5 million Series B-3 financing to expand clinical programs.
(press release)

May 14, 2019

Actuate Therapeutics completes $21.7 million Series B financing. (press release)

December 17, 2018

Actuate Therapeutics opens Phase 1 / 2 Clinical Study of 9-ING-41 in Patients with Refractory Cancers.
(press release)

May 18, 2018

Dr. Torry Tucker presents research on the effect of 9-ING-41 in attenuating Idiopathic Pulmonary Fibrosis at the annual meeting of the American Thoracic Society. (poster)

April 16, 2018

Dr. Li Ding presents research findings on GSK inhibition and 9-ING-41 synergizes with chemotherapy to inhibit pancreatic tumor growth in vivo at AACR Annual Meeting. (poster)

February 15, 2018

Actuate Therapeutics announces FDA acceptance of IND application for 9-ING-41 and clearance to proceed with clinical study in patients with advanced cancers
(press release)

January 15, 2018

Actuate Therapeutics submits IND application for treatment of refractory cancers.
(press release)

October 26, 2017

Actuate Therapeutics receives rare pediatric disease designation for 9-ING-41 for treatment of neuroblastoma.
(press release)

August 18, 2017

FDA grants an additional Orphan Drug Designation for 9-ING-41 for the treatment of neuroblastoma.

June 17, 2017

Actuate closes Series A Financing totaling $3.8M

April 3, 2017

Dr. Matsangou presents research on GSK-3B and its role in head and neck carcinoma at the AACR meeting in Washington, DC.

March 31, 2017

Actuate technologies featured in the Molecular Pathways special feature section in the journal Clinical Cancer Research.

(press release)    (journal article)

March 1, 2017

Dr. Francis J. Giles joins Actuate as Chief Medical Officer. (press release)

March 29, 2016

FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma.

December 18, 2015

Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients.

December 11, 2015

Actuate completes initial financing.

November 19, 2015

Andrey Ugolkov presents his work the use of 9-ING-41 in treatment-sensitive and treatment-resistant glioblastoma at the Society of Neuro Oncology meeting. (see attachment)

October 29, 2015

Actuate Forms Scientific Advisory Board

April 20, 2015

Drs. Dubrovsky and Ugolkov present research on GSK-3B and its role in neuroblastoma and glioblastoma at the AACR meeting in Philadelphia.
(Poster 1)
(Poster 2)

April 16, 2015

License agreements are executed with both UIC and Northwestern for the technology and know-how that serves as the foundational intellectual property for Actuate Therapeutics.

Jan 16, 2015

Company is incorporated as Apotheca Therapeutics, Inc, a Delaware C Corp, with Headquarters in Fort Worth, Texas.